Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2006

View Archived Issues

Phase I data on RC-1291, a ghrelin mimetic targeted for cancer cachexia

AEterna Zentaris report on novel peptidomimetic GnRH antagonist

Pfizer reports on weekly rhGh injection

Barr submits regulatory filings for acquisition of Pliva

Avicena studies ALS-08 combination therapies for ALS

Noopept shows therapeutic potential for Alzheimer's disease

Japanese agreement signed for Zevalin

DL-06001 and DL-06002 studied for symptoms of Parkinson's disease

Phase III study of TH-9507 for HIV-associated lipodystrophy cleared to continue

Phase Ib study investigates Reolysin/radiation therapy in advanced cancers

Novozymes acquires Delta Biotechnology

Sanctura XR reduces overactive bladder symptoms with good tolerability

DMXB-A improves neurocognition in schizophrenia patients

Phase I results encouraging with EKB-569 in advanced cancer patients

Pirfenidone pharmacokinetics assessed in rats, dogs and humans

Intraarticular steroids beneficial in hip osteoarthritis

Cook's Zilver stent approved for vascular use

MabThera approved for rheumatoid arthritis in Europe

European approval for MabThera as maintenance therapy in NHL

Pharmacokinetic profile of Huperzine A prodrug ZT-1 reported

Selective ACAT1 inhibitor shows plaque-stabilizing activity in a mouse model of atherosclerosis

New therapeutic agents for HIV infection disclosed in recent patents

Novel PPAR ligands for dermatological disorders described in recent Galderma patent

New coagulation factor Xa inhibitors prepared and tested

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...